Removal of therapeutic anti-lymphocyte antibodies from human sera prior to anti-human leukocyte antibody testing

• Published in: Journal of immunological methods 2005-05, Vol.300 (1), p.192-199
• Main Authors: Bearden, Christopher M., Book, Benita K, Sidner, Richard A., Pescovitz, Mark D.
• Format: Article
• Language: English
• Subjects: Animals; Antibodies; Antilymphocyte Serum - blood; Antilymphocyte Serum - isolation & purification; Antilymphocyte Serum - therapeutic use; Biological and medical sciences; Crossmatch; Flow Cytometry; Fundamental and applied biological sciences. Psychology; Fundamental immunology; Histocompatibility; Humans; Immunomagnetic Separation; Immunosorbent Techniques; Interference; Leukocytes - immunology; Mice; Molecular immunology; Muromonab-CD3 - blood; Muromonab-CD3 - isolation & purification; Muromonab-CD3 - therapeutic use; PRA; Rabbits; T-Lymphocytes - immunology; Techniques; Transplant
• ISSN: 0022-1759; 1872-7905
• DOI: 10.1016/j.jim.2005.03.001

Both monoclonal (e.g. Orthoclone (OKT3®), rituximab) and polyclonal (e.g. ATGAM®, Thymoglobulin® (Thymo)) anti-lymphocyte Abs (ALAs) are used extensively in organ transplantation for immunosuppression induction, desensitization, and treatment of acute rejection. ALAs often interfere with post transplant immunologic monitoring. We describe a method that uses magnetic beads to selectively remove ALAs from patient serum. Rabbit anti-mouse Fc-specific (180 μg), or rabbit anti-mouse Fab-specific (180 μg), or rabbit anti-horse heavy and light chain-specific and rabbit anti-horse F(ab') 2 (200 μg) (Jackson Immunoresearch) was adsorbed to 6.7 × 10 8 Dynabeads M-280 conjugated with sheep anti-rabbit IgG (Dynal Biotech). Fifty microliters of normal human serum (NHS) with 2 μg/ml of OKT3 or 100 μg/ml ATGAM, Thymo, or rituximab were incubated with conjugated beads for several incubations. NHS containing ALAs before and after treatment by the protocol were incubated with human lymphocytes and labeled with FITC-antibody to immunoglobulin of the species used to produce the particular ALA. Residual ALA was determined using flow cytometry. Average median channel for serum with or without ALA was 11.1 and 0.120, respectively for OKT3; 64.4 and 0.344 for ATGAM; 108.5 and 0.200 for Thymo; and 1022.5 and 11.4 for rituximab. Treatment lowered the median channel for serum with OKT3 to 0.103, 0.309 for ATGAM, 0.199 for Thymo, and 12.1 for rituximab. ALAs can be effectively removed from serum by the use of magnetic beads conjugated with Ab specific for ALA thereby permitting immunologic monitoring without interference.